Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer

Trial Profile

Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs GM 102 (Primary)
  • Indications Gynaecological cancer
  • Focus Adverse reactions; First in man
  • Sponsors GamaMabs Pharma
  • Most Recent Events

    • 18 Jul 2017 Planned number of patients changed from 51 to 84.
    • 18 Jul 2017 Planned End Date changed from 1 Dec 2019 to 30 Mar 2020.
    • 18 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top